

## Course Detail

**MMWR Weekly – April 13, 2012**

**Course Number: SS1747-04132012**

**CE Origination Date: April 13, 2012**

**CE Expiration Date: May 28, 2012**

## Content Experts/Prepares

### **Antibodies Cross-Reactive to Influenza A (H3N2) Variant Virus and Impact of 2010–11 Seasonal Influenza Vaccine on Cross-Reactive Antibodies — United States**

Amanda Balish, MS, Influenza Division, National Center for Immunization and Respiratory Diseases, CDC  
Alicia Branch, PhD, Influenza Division, National Center for Immunization and Respiratory Diseases, CDC  
Peter Browning, Influenza Division, National Center for Immunization and Respiratory Diseases, CDC  
Nancy Cox, PhD, Influenza Division, National Center for Immunization and Respiratory Diseases, CDC  
Alicia Fry, MD, Influenza Division, National Center for Immunization and Respiratory Diseases, CDC  
Eric Gillis, MS, Influenza Division, National Center for Immunization and Respiratory Diseases, CDC  
Kathy Hancock, PhD, Influenza Division, National Center for Immunization and Respiratory Diseases, CDC  
Jacqueline M. Katz, PhD, Influenza Division, National Center for Immunization and Respiratory Diseases, CDC  
Heather Noland, Influenza Division, National Center for Immunization and Respiratory Diseases, CDC  
Carrie Reed, MD, Influenza Division, National Center for Immunization and Respiratory Diseases, CDC  
Leilani Thomas, Influenza Division, National Center for Immunization and Respiratory Diseases, CDC  
Vic Veguilla, MPH, Influenza Division, National Center for Immunization and Respiratory Diseases, CDC

### **Rabies Risk Assessments of Exposures to a Bat on a Commercial Airliner — United States, August 2011**

Michael L. Bartholomew, MD, EIS officers, CDC  
Teal R. Bell, Division of Global Migration and Quarantine, CDC  
Danielle Buttke, DVM, PhD, EIS officer, CDC  
Nicole J. Cohen, MD., Division of Global Migration and Quarantine, CDC  
Jeffrey P. Davis, MD, Wisconsin Division of Public Health  
James Kazmierczak, DVM, Wisconsin Division of Public Health  
Nina Marano, DVM, Division of Global Migration and Quarantine, CDC  
Karen Marienau, MD, Division of Global Migration and Quarantine, CDC  
Sergio Recuenco, MD, DrPh, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, CDC  
Charles Rupprecht, VMD, PhD, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, CDC  
Danielle Tack, DVM, EIS officers, CDC

### **Human Orf Virus Infection from Household Exposures — United States, 2009–2011**

Jennifer M. Bass, CDC Experience Applied Epidemiology Fellow  
Yuval Bibi, MD, Dermatology Department, Harvard Vanguard Medical Associates, Boston  
Isaac I. Bogoch, MD, Division of Infectious Diseases, Massachusetts General Hospital, Boston  
Catherine M. Brown, DVM, State Public Health Veterinarian, Massachusetts, Department of Public Health

Esther Chernak, MD, Philadelphia Department of Public Health

George Cotsarelis, MD, Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia

Whitni Davidson, MPH, Division of High Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, CDC

Voraphat Dejsuphong, MD, International Graduate Dermatology Program, Boston University School of Medicine

David Enis, MD, Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia

Rajesh T. Gandhi, MD, Division of Infectious Diseases, Massachusetts General Hospital, Boston

Yu Li, PhD, Division of High Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, CDC

Donald Poretz, MD, Inova Fairfax Hospital, Falls Church, Virginia

Danielle M. Tack, DVM, EIS Officer, CDC

Hui Zhao, MD, Division of High Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, CDC

### **Disclosure**

CDC, our planners, and our content experts wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters.

Presentations will not include any discussion of the unlabeled use of a product or a product under investigational use.

No commercial support.

**Mechanism(s) to Resolve Real and Perceived Conflicts of Interest: N/A**